Breast reconstruction surgery means meticulous craftsmanship by experienced surgeons
Reconstructing a removed breast is part of the treatment path of many breast cancer patients. The goal of the surgery...
Read moreMon–Thu 8–18, Fri 8–16
Hodgkin lymphoma is a cancer of the lymphatic tissue. Usually, it starts in a lymph node and the first detected sign is an enlarged lymph node.
Hodgkin lymphoma is most typically diagnosed in young adults. Today, its prognosis is good. Hodgkin lymphoma is classified into subcategories (classic and lymphocyte-predominant) by stage.
The exact cause of Hodgkin lymphoma is not known. It is found more frequently than average in people with a disease that leads to immunodeficiency (such as AIDS) and people who are using medication that causes immunodeficiency (such as organ transplant medication). Epstein-Barr infection (mononucleosis) has been found to be a risk factor.
The only initial sign of Hodgkin lymphoma may be a swollen lymph node in the neck. Most patients are symptom-free at the time of diagnosis. The symptoms partly depend on the location of the tumor. A painless cough may be associated with the disease if mediastinal lymph nodes are enlarged. Some patients experience general symptoms, so-called ‘B’ symptoms, such as fever, sweating and tiredness.
The disease is diagnosed by examining a piece of tissue, usually obtained by removing a swollen lymph node. Once the diagnosis is established, the cancer is staged. Usually, this involves a CT scan of the body and an FDG-PET/CT scan. A bone marrow biopsy may also be performed to ensure successful staging.
The choice of treatment depends on the stage of disease and the symptoms. The most common treatments include chemotherapy and radiotherapy and combinations thereof. If the disease recurs, biological targeted agents may be used, and stem cell transplantation may be included in the treatment.
Reconstructing a removed breast is part of the treatment path of many breast cancer patients. The goal of the surgery...
Read moreNew forms of treatment based on molecular diagnostics enable more and more patients to completely recover from cancer, and make...
With a transaction signed on 2 September 2024, Mehiläinen has acquired Docrates Ltd, as a result of which Docrates Cancer...
On 27, August 2024, the Finnish Competition and Consumer Authority (FCCA) approved the merger of Mehiläinen and Docrates Cancer Center....
Contact us!
Mon-Thu 8:00-18:00, Fri 8:00-16:00